Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMB72
- Development stage
- Phase 1
- Lead developer
- Massachusetts General Hospital
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Oral, Transdermal
01
Overview
BMB72 is a live attenuated bacterial vaccine vector derived from *Listeria monocytogenes*. It is genetically engineered with deletions in the *actA* and *plcB* genes, which significantly reduce its virulence by impairing its ability to spread cell-to-cell and escape from phagosomes, respectively. The vector is designed to express and secrete the nucleoprotein (NP) of the Influenza A virus. By utilizing the natural intracellular lifecycle of *Listeria*, BMB72 delivers the viral antigen directly to the cytosol of antigen-presenting cells, thereby facilitating the induction of robust CD8+ T-cell responses and mucosal immunity. It has been investigated in early-phase clinical trials for both oral and transcutaneous administration, sometimes in combination with adjuvants like cholera toxin.
- Other names
- Listeria monocytogenes BMB72actA/plcB-deleted Listeria monocytogenes expressing influenza A nucleoprotein
02
Targets
NP (Taï Forest ebolavirus nucleoprotein)
Beyond the preview
Go deeper on BMB72.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMB72.